Hospital
Crestview Hospital Company, LLC
Crestview Hospital Company, LLC was paid $8.15M by Medicaid between Jan 2018 and Dec 2024, across 201 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoCRESTVIEW HOSPITAL COMPANY, LLC
CRESTVIEW, FL 32539
CRESTVIEW, FL 32539
33aNPI1104897859assigned 01/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.15M
24GClaims474,886
24DCodes billed201
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#60 of 163
Median peer was paid$4.77M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,416 | $603K | |
| 2019 | 80,875 | $1.19M | |
| 2020 | 74,050 | $946K | |
| 2021 | 90,111 | $1.30M | |
| 2022 | 95,140 | $1.82M | |
| 2023 | 70,710 | $1.40M | |
| 2024incomplete | 36,584 | $889K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 28,187 | 24,603 | $1.73M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 17,436 | 14,365 | $934K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.3% | 6,079 | 5,491 | $429K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.2% | 4,703 | 3,644 | $427K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.0% | 5,196 | 4,680 | $410K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.8% | 6,789 | 1,706 | $392K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 2,890 | 2,444 | $389K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.5% | 3,017 | 2,404 | $366K |
| 80053 | Comprehensive metabolic panel | 3.4% | 22,308 | 16,919 | $275K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 5,622 | 4,390 | $227K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 4,086 | 2,302 | $207K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.4% | 498 | 456 | $199K |
189 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 3,123 | $168K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 9,614 | $162K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 9,539 | $101K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 3,541 | $101K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 6,894 | $89K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 675 | $89K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,385 | $73K |
| 83880 | <1% | 3,237 | $65K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,471 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,297 | $48K |
| 86901 | <1% | 1,368 | $45K | |
| 87420 | <1% | 2,919 | $36K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,080 | $36K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,561 | $34K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,365 | $33K |
| G0378 | Hospital observation service, per hour | <1% | 1,777 | $29K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 509 | $28K |
| 74018 | <1% | 1,203 | $27K | |
| 85730 | <1% | 4,336 | $27K | |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | <1% | 1,222 | $27K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,570 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,269 | $26K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 561 | $25K |
| 84484 | <1% | 8,978 | $25K | |
| 67311 | <1% | 15 | $25K | |
| 86900 | <1% | 400 | $25K | |
| 81003 | <1% | 10,308 | $25K | |
| 95811 | <1% | 59 | $24K | |
| 73610 | <1% | 755 | $22K | |
| 73564 | <1% | 801 | $21K | |
| 81025 | <1% | 4,407 | $21K | |
| 76641 | <1% | 345 | $21K | |
| 85610 | <1% | 6,345 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,453 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 384 | $19K |
| 73630 | <1% | 930 | $18K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,037 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,089 | $18K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 950 | $17K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,528 | $17K |
| 86850 | <1% | 1,810 | $17K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,848 | $17K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 391 | $16K |
| 80306 | <1% | 2,549 | $15K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 304 | $14K |
| 83735 | <1% | 6,735 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,935 | $13K |
| 73030 | <1% | 692 | $13K | |
| 81001 | <1% | 9,322 | $13K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,196 | $12K |
| 97161 | <1% | 249 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,008 | $12K |
| 87186 | <1% | 2,657 | $12K | |
| 84702 | <1% | 1,645 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,291 | $11K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 276 | $11K |
| 73130 | <1% | 406 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,539 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 664 | $9K |
| 73110 | <1% | 432 | $9K | |
| 88304 | <1% | 103 | $9K | |
| 82550 | <1% | 3,582 | $9K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,516 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,459 | $8K |
| 80061 | Lipid panel | <1% | 2,953 | $8K |
| 82553 | <1% | 1,650 | $8K | |
| 93971 | <1% | 160 | $8K | |
| 72110 | <1% | 325 | $7K | |
| 84703 | <1% | 3,467 | $7K | |
| 82962 | <1% | 1,459 | $7K | |
| 99499 | <1% | 61 | $6K | |
| 83690 | <1% | 7,717 | $6K | |
| 71250 | <1% | 300 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,876 | $5K |
| 87045 | <1% | 75 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,406 | $5K |
| 80076 | <1% | 2,210 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 868 | $5K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 233 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,687 | $5K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 909 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 771 | $4K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 78 | $4K |
| 76801 | <1% | 373 | $4K | |
| 82805 | <1% | 306 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,377 | $3K |
| 84112 | <1% | 81 | $3K | |
| 72131 | <1% | 161 | $3K | |
| 87070 | <1% | 381 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 10,638 | $3K |
| 87077 | <1% | 2,784 | $3K | |
| 73080 | <1% | 80 | $2K | |
| 70496 | <1% | 17 | $2K | |
| 76770 | <1% | 14 | $2K | |
| 88342 | <1% | 451 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,741 | $2K |
| 87081 | <1% | 7,062 | $1K | |
| 87810 | <1% | 231 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 475 | $1K |
| 97162 | <1% | 35 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 486 | $1K |
| 82150 | <1% | 1,204 | $1K | |
| 87400 | <1% | 11,060 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,576 | $1K |
| 82607 | <1% | 531 | $1K | |
| 85379 | <1% | 1,698 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 19 | $1K |
| 94060 | <1% | 38 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 910 | $992.38 |
| 82950 | <1% | 371 | $863.82 | |
| 84439 | <1% | 1,195 | $812.71 | |
| 87210 | <1% | 375 | $791.79 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,990 | $769.93 |
| 86141 | <1% | 1,755 | $747.50 | |
| 82728 | <1% | 369 | $703.71 | |
| 73140 | <1% | 13 | $672.64 | |
| 83970 | <1% | 378 | $644.72 | |
| 83605 | <1% | 1,431 | $644.13 | |
| 85651 | <1% | 1,027 | $636.86 | |
| 86803 | <1% | 743 | $622.53 | |
| 82746 | <1% | 211 | $587.91 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 372 | $509.87 |
| 80299 | <1% | 850 | $501.23 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 409 | $498.22 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 200 | $497.23 |
| 73090 | <1% | 12 | $497.05 | |
| 86592 | <1% | 884 | $490.37 | |
| 87040 | <1% | 2,478 | $471.45 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 821 | $441.45 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 146 | $437.58 |
| 84100 | <1% | 1,282 | $405.44 | |
| 94760 | <1% | 1,667 | $333.88 | |
| 83540 | <1% | 522 | $320.92 | |
| 87340 | <1% | 600 | $301.93 | |
| 00811 | <1% | 145 | $298.41 | |
| 84156 | <1% | 630 | $297.90 | |
| 73502 | <1% | 33 | $290.26 | |
| 86762 | <1% | 245 | $260.44 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 382 | $223.95 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 16 | $194.30 |
| 85027 | <1% | 225 | $173.47 | |
| 82247 | <1% | 512 | $169.38 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $166.18 |
| 83550 | <1% | 318 | $163.39 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 361 | $158.31 |
| 82043 | <1% | 146 | $154.25 | |
| 82140 | <1% | 233 | $151.99 | |
| 70486 | <1% | 20 | $141.76 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 137 | $136.46 |
| 92558 | <1% | 18 | $124.93 | |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | <1% | 69 | $111.37 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 112 | $110.84 |
| 82570 | <1% | 262 | $90.81 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 15 | $90.00 |
| 29125 | <1% | 12 | $87.60 | |
| 87209 | <1% | 34 | $86.81 | |
| 83021 | <1% | 72 | $86.78 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 361 | $65.91 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 453 | $61.73 |
| 87177 | <1% | 34 | $55.77 | |
| 84520 | <1% | 13 | $54.05 | |
| 82565 | <1% | 13 | $54.05 | |
| 94726 | <1% | 36 | $48.30 | |
| 94729 | <1% | 38 | $48.30 | |
| 84550 | <1% | 263 | $29.17 | |
| 00140 | <1% | 144 | $14.00 | |
| 96376 | <1% | 550 | $3.60 | |
| 83615 | <1% | 34 | $3.13 | |
| 82009 | <1% | 37 | $1.29 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 51 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 68 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 200 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 17 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 13 | $0.00 |
| 70498 | 0% | 17 | $0.00 | |
| C1769 | Guide wire | 0% | 19 | $0.00 |
| 00813 | 0% | 13 | $0.00 | |
| 88313 | 0% | 165 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 59 | $0.00 |
| 90715 | 0% | 16 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 13 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 14 | $0.00 |
| 36600 | 0% | 79 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 18 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 315 | $0.00 |
| 99152 | 0% | 20 | $0.00 | |
| 73590 | 0% | 20 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 14 | $0.00 |
| 94664 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.